Potential of NK cells in multiple Myeloma therapy

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018 Jan;68(1):7–30.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014 Nov;15(12):e538–48.
   PubMed Web of Science ®Google Scholar
• Abel AM, Yang C, Thakar MS, et al. Natural Killer Cells: development, Maturation, and Clinical Utilization. Front Immunol. 2018;9:1869.
   PubMed Web of Science ®Google Scholar
• Seaman WE, Sleisenger M, Eriksson E et al. Depletion of natural killer cells in mice by monoclonal antibody to NK-1.1. Reduction in host defense against malignancy without loss of cellular or humoral immunity. J Immunol. 1987 Jun 15;138(12):4539–4544.
   PubMed Web of Science ®Google Scholar
• Strayer DR, Carter WA, Mayberry SD, et al. Low natural cytotoxicity of peripheral blood mononuclear cells in individuals with high familial incidences of cancer. Cancer Res. 1984 Jan;44(1):370–374.
   PubMed Web of Science ®Google Scholar
• Imai K, Matsuyama S, Miyake S, et al. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet. 2000 Nov 25;356(9244):1795–1799.
   PubMed Web of Science ®Google Scholar
• Caligiuri MA Human natural killer cells. Blood. 2008 Aug 1;112(3):461–469.
   PubMed Web of Science ®Google Scholar
• Godfrey J, Benson DM Jr. The role of natural killer cells in immunity against multiple myeloma. Leuk Lymphoma. 2012 Sep;53(9):1666–1676.
   PubMed Web of Science ®Google Scholar
• Ljunggren HG, Karre K Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J Exp Med. 1985 Dec 1;162(6):1745–1759.
   PubMed Web of Science ®Google Scholar
• Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer. 2016 Jan;16(1):7–19.
   PubMed Web of Science ®Google Scholar
• Pegram HJ, Andrews DM, Smyth MJ, et al. Activating and inhibitory receptors of natural killer cells. Immunol Cell Biol 2011 Feb;89(2):216–224.
   PubMed Web of Science ®Google Scholar
• Kumar S Natural killer cell cytotoxicity and its regulation by inhibitory receptors. Immunology. 2018 Jul;154(3):383–393.
   PubMed Web of Science ®Google Scholar
• Krzewski K, Strominger JL The Killer’s Kiss: the many functions of NK cell immunological synapses. Curr Opin Cell Biol. 2008 Jul 17;20(5):597–605.
   PubMed Web of Science ®Google Scholar
• Krzewski K, Coligan J. Human NK cell lytic granules and regulation of their exocytosis [Review]. Front Immunol 2012 2012 November 09;3 335.
   PubMed Web of Science ®Google Scholar
• Cullen SP, Martin SJ Fas and TRAIL ‘death receptors’ as initiators of inflammation: implications for cancer. Semin Cell Dev Biol 2015 Mar;39:26–34.
   PubMed Web of Science ®Google Scholar
• Chester C, Fritsch K, Kohrt HE Natural Killer Cell Immunomodulation: targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer Immunotherapy. Front Immunol 2015;6:601.
   PubMed Web of Science ®Google Scholar
• Famularo G, D’Ambrosio A, Quintieri F, et al.Natural killer cell frequency and function in patients with monoclonal gammopathies. J Clin Lab Immunol 1992;37(3):99–109.
   PubMedGoogle Scholar
• Herrmann F, Lochner A, Jauer B, et al.Lymphocyte subsets in the peripheral blood of patients with multiple myeloma and benign monoclonal gammopathy. Klinische Wochenschrift 1983 Aug 15;61(16):819–821.
   PubMedGoogle Scholar
• Omede P, Boccadoro M, Gallone G, et al.Multiple myeloma: increased circulating lymphocytes carrying plasma cell-associated antigens as an indicator of poor survival. Blood. 1990 Oct 1;76(7):1375–1379.
   PubMed Web of Science ®Google Scholar
• Österborg A, Nilsson B, Björkholm M, et al. Natural killer cell activity in monoclonal gammopathies: relation to disease activity. Eur J Haematol 1990;45(3):153–157.
   PubMed Web of Science ®Google Scholar
• Pessoa de Magalhaes RJ, Vidriales MB, Paiva B, et al. Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica. 2013 Jan;98(1):79–86.
   PubMed Web of Science ®Google Scholar
• Tienhaara A, Pelliniemi TT Peripheral blood lymphocyte subsets in multiple myeloma and monoclonal gammopathy of undetermined significance. Clin Lab Haematol 1994 Sep;16(3):213–223.
   PubMedGoogle Scholar
• Van den Hove LE, Meeus P, Derom A, et al.Lymphocyte profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: flow-cytometric characterization and analysis in a two-dimensional correlation biplot. Ann Hematol 1998 Jun;76(6):249–256.
   PubMed Web of Science ®Google Scholar
• De Rossi G, De Sanctis G, Bottari V, et al.Surface markers and cytotoxic activities of lymphocytes in monoclonal gammopathy of undetermined significance and untreated multiple myeloma. Cancer Immunol Immunother 1987;25(2):133–136.
   PubMed Web of Science ®Google Scholar
• Fauriat C, Mallet F, Olive D, et al.Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma. Leukemia. 2006 Apr;20(4):732–733.
   PubMed Web of Science ®Google Scholar
• Garcia-Sanz R, Gonzalez M, Orfao A, et al.Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications. Br J Haematol. 1996 Apr;93(1):81–88.
   PubMed Web of Science ®Google Scholar
• Gonzalez M, San Miguel JF, Gascon A, et al.Increased expression of natural-killer-associated and activation antigens in multiple myeloma. Am J Hematol. 1992 Feb;39(2):84–89.
   PubMed Web of Science ®Google Scholar
• Jurisic V, Srdic T, Konjevic G, et al.Clinical stage-depending decrease of NK cell activity in multiple myeloma patients. Med Oncol. 2007;24(3):312–317.
   PubMed Web of Science ®Google Scholar
• King MA, Radicchi-Mastroianni MA Natural killer cells and CD56+ T cells in the blood of multiple myeloma patients: analysis by 4-colour flow cytometry. Cytometry. 1996 Jun 15;26(2):121–124.
   PubMedGoogle Scholar
• Nielsen H, Nielsen HJ, Tvede N, et al. Immune dysfunction in multiple myeloma. Reduced natural killer cell activity and increased levels of soluble interleukin-2 receptors. Apmis. 1991 Apr;99(4):340–346.
   PubMed Web of Science ®Google Scholar
• Ogmundsdottir HM Natural killer cell activity in patients with multiple myeloma. Cancer Detect Prev. 1988;12(1–6):133–143.
   PubMedGoogle Scholar
• Schutt P, Brandhorst D, Stellberg W, et al.Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections. Leuk Lymphoma. 2006 Aug;47(8):1570–1582.
   PubMed Web of Science ®Google Scholar
• Bernal M, Garrido P, Jiménez P, et al. Changes in activatory and inhibitory natural killer (NK) receptors may induce progression to multiple myeloma: implications for tumor evasion of T and NK cells. Hum Immunol. 2009 2009 Oct 01;70(10):854–857.
   PubMed Web of Science ®Google Scholar
• Sarkar S, van Gelder M, Noort W, et al.Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2A. Cancer Immunol Immunother. 2015 Aug;64(8):951–963.
   PubMed Web of Science ®Google Scholar
• Mahaweni NM, Ehlers FAI, Sarkar S, et al.NKG2A expression is not per se detrimental for the anti-multiple myeloma activity of activated natural killer cells in an in vitro system mimicking the tumor microenvironment. Front Immunol. 2018;9:1415.
   PubMed Web of Science ®Google Scholar
• Yadav M, Green C, Ma C, et al. Tigit, CD226 and PD-L1/PD-1 are highly expressed by marrow-infiltrating t cells in patients with multiple myeloma. Blood. 2016;128(22): 2102–2102.
   Google Scholar
• Minnie SA, Kuns RD, Gartlan KH, et al.Myeloma-escape after stem cell transplantation is a consequence of T cell exhaustion and is prevented by TIGIT blockade. Blood. 2018 Oct 18;132(16):1675–1688.
   PubMed Web of Science ®Google Scholar
• Guillerey C, Harjunpää H, Carrié N, et al. TIGIT immune checkpoint blockade restores CD8+ T cell immunity against multiple myeloma. Blood. 2018 Oct 18;132(16):1689–1694.
   PubMed Web of Science ®Google Scholar
• Benson DM Jr., Bakan CE, Mishra A, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood. 2010 Sep 30;116(13):2286–2294.
   PubMed Web of Science ®Google Scholar
• Costello RT, Boehrer A, Sanchez C, et al.Differential expression of natural killer cell activating receptors in blood versus bone marrow in patients with monoclonal gammopathy. Immunology. 2013 Jul;139(3):338–341.
   PubMed Web of Science ®Google Scholar
• Jinushi M, Vanneman M, Munshi NC, et al.MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci USA 2008;105(4):1285–1290.
   PubMed Web of Science ®Google Scholar
• El-Sherbiny YM, Meade JL, Holmes TD, et al.The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res. 2007 Sep 15;67(18):8444–8449.
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Menard C, Terme M, et al.CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med. 2005 Oct 17;202(8):1075–1085.
   PubMed Web of Science ®Google Scholar
• Trotta R, Dal Col J, Yu J, et al. TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. J Immunol. 2008 Sep 15;181(6):3784–3792.
   PubMed Web of Science ®Google Scholar
• Yu J, Wei M, Becknell B, et al.Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells. Immunity. 2006 May;24(5):575–590.
   PubMed Web of Science ®Google Scholar
• Guillerey C, Nakamura K, Vuckovic S, et al.Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies. Cell Mol Life Sci 2016 Apr;73(8):1569–1589.
   PubMed Web of Science ®Google Scholar
• Ali TH, Pisanti S, Ciaglia E, et al.Enrichment of CD56(dim)KIR + CD57 + highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients. Nat Commun. 2014 Dec 4;5:5639.
   PubMed Web of Science ®Google Scholar
• Kang YJ, Jeung IC, Park A, et al.An increased level of IL-6 suppresses NK cell activity in peritoneal fluid of patients with endometriosis via regulation of SHP-2 expression. Hum Reprod. 2014 Oct 10;29(10):2176–2189.
   PubMed Web of Science ®Google Scholar
• Cifaldi L, Prencipe G, Caiello I, et al.Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome. Arthritis Rheumatol (Hoboken, NJ) 2015 Nov;67(11):3037–3046.
   PubMed Web of Science ®Google Scholar
• Dehghanifard A, Kaviani S, Abroun S, et al. Various signaling pathways in multiple myeloma cells and effects of treatment on these pathways. Clin Lymphoma Myeloma Leukemia. 2018 2018 May 01;18(5):311–320.
   PubMed Web of Science ®Google Scholar
• Nachbaur DM, Herold M, Maneschg A, et al. Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters. Ann Hematol. 1991 Feb-Mar;62(2–3):54–58.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Kishimoto T The biology and medical implications of interleukin-6. Cancer Immunol Res. 2014 Apr;2(4):288–294.
   PubMed Web of Science ®Google Scholar
• Pedersen L, Idorn M, Olofsson GH, et al. Voluntary running suppresses tumor growth through epinephrine- and IL-6-dependent NK cell mobilization and redistribution. Cell Metab. 2016 Mar 8;23(3):554–562.
   PubMed Web of Science ®Google Scholar
• Kozlowska AK, Tseng HC, Kaur K, et al.Resistance to cytotoxicity and sustained release of interleukin-6 and interleukin-8 in the presence of decreased interferon-gamma after differentiation of glioblastoma by human natural killer cells. Cancer Immunol Immunother 2016 Sep;65(9):1085–1097.
   PubMed Web of Science ®Google Scholar
• Kovacs E Interleukin-6 leads to interleukin-10 production in several human multiple myeloma cell lines. Does interleukin-10 enhance the proliferation of these cells? Leuk Res. 2010 Jul;34(7):912–916.
   PubMed Web of Science ®Google Scholar
• Alexandrakis MG, Goulidaki N, Pappa CA, et al. Interleukin-10 induces both plasma cell proliferation and angiogenesis in multiple myeloma. Pathol Oncol Res 2015 Sep;21(4):929–934.
   PubMed Web of Science ®Google Scholar
• Pittari G, Vago L, Festuccia M, et al.Restoring natural killer cell immunity against multiple myeloma in the era of new drugs. Front Immunol. 2017;8:1444.
   PubMed Web of Science ®Google Scholar
• Lu ZY, Bataille R, Poubelle P, et al.An interleukin 1 receptor antagonist blocks the IL-1-induced IL-6 paracrine production through a prostaglandin E2-related mechanism in multiple myeloma. Stem Cells (Dayton, Ohio) 1995 Aug;13 Suppl 2:28–34.
   PubMedGoogle Scholar
• Martinet L, Jean C, Dietrich G, et al.PGE2 inhibits natural killer and gamma delta T cell cytotoxicity triggered by NKR and TCR through a cAMP-mediated PKA type I-dependent signaling. Biochem Pharmacol 2010 Sep 15;80(6):838–845.
   PubMed Web of Science ®Google Scholar
• Bonanno G, Mariotti A, Procoli A, et al. Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma [journal article]. J Transl Med. 2012 December 11;10(1):247.
   PubMedGoogle Scholar
• Sarkar S, Germeraad WTV, Rouschop KMA, et al. Hypoxia induced impairment of NK cell cytotoxicity against multiple myeloma can be overcome by IL-2 activation of the NK cells. PloS One. 2013;8(5):e64835.
   PubMed Web of Science ®Google Scholar
• Ponzetta A, Benigni G, Antonangeli F, et al.Multiple myeloma impairs bone marrow localization of effector natural killer cells by altering the chemokine microenvironment. Cancer Res 2015 Nov 15;75(22):4766–4777.
   PubMed Web of Science ®Google Scholar
• Gonsalves WI, Buadi FK, Ailawadhi S, et al. Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus statement. Bone Marrow Transplant. 2019 Mar;54(3):353–367.
   Web of Science ®Google Scholar
• Porrata LF, Gertz MA, Inwards DJ, et al.Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-hodgkin lymphoma. Blood. 2001 Aug 1;98(3):579–585.
   PubMed Web of Science ®Google Scholar
• Rueff J, Medinger M, Heim D, et al.Lymphocyte subset recovery and outcome after autologous hematopoietic stem cell transplantation for plasma cell myeloma. Biol Blood Marrow Transplant. 2014 Jun;20(6):896–899.
   PubMed Web of Science ®Google Scholar
• Savani BN, Mielke S, Adams S, et al. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia [original article]. Leukemia. 2007 Aug 02 online;21:2145.
   PubMed Web of Science ®Google Scholar
• Savani BN, Rezvani K, Mielke S, et al. Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2006;107(4):1688–1695.
   PubMed Web of Science ®Google Scholar
• Burwick N, Sharma S Glucocorticoids in multiple myeloma: past, present, and future [journal article]. Ann Hematol 2019 January 01;98(1):19–28.
   PubMed Web of Science ®Google Scholar
• Sharma S, Lichtenstein A Dexamethasone-induced apoptotic mechanisms in myeloma cells investigated by analysis of mutant glucocorticoid receptors. Blood 2008;112(4):1338–1345.
   PubMed Web of Science ®Google Scholar
• Greenstein S, Ghias K, Krett NL, et al.Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies. Clin Cancer Res 2002;8(6):1681–1694.
   PubMed Web of Science ®Google Scholar
• Chauhan D, Hideshima T, Pandey P, et al.RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells. Oncogene. 1999 Nov 18;18(48):6733–6740.
   PubMed Web of Science ®Google Scholar
• Burwick N, Zhang MY, de la Puente P, et al.The eIF2-alpha kinase HRI is a novel therapeutic target in multiple myeloma. Leuk Res. 2017 2017 Apr 01;55:23–32.
   PubMed Web of Science ®Google Scholar
• Eddy JL, Krukowski K, Janusek L, et al. Glucocorticoids regulate natural killer cell function epigenetically. Cell Immunol. 2014 2014 Jul 01;290(1):120–130.
   PubMed Web of Science ®Google Scholar
• Krukowski K, Eddy J, Kosik KL, et al.Glucocorticoid dysregulation of natural killer cell function through epigenetic modification. Brain Behav Immun 2011 Feb;25(2):239–249.
   PubMed Web of Science ®Google Scholar
• Ito T, Ando H, Suzuki T, et al. Identification of a primary target of thalidomide teratogenicity. Science 2010 Mar 12;327(5971):1345–1350.
   PubMed Web of Science ®Google Scholar
• Zhu YX, Braggio E, Shi CX, et al.Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood. 2011 Nov 3;118(18):4771–4779.
   PubMed Web of Science ®Google Scholar
• Kronke J, Udeshi ND, Narla A, et al.Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 2014 Jan 17;343(6168):301–305.
   PubMed Web of Science ®Google Scholar
• Lu G, Middleton RE, Sun H, et al.The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 2014 Jan 17;343(6168):305–309.
   PubMed Web of Science ®Google Scholar
• Bjorklund CC, Lu L, Kang J, et al. Rate of CRL4CRBN substrate ikaros and aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4 [original article]. Blood Cancer J. 2015 Oct 02 online;5:e354.
   PubMed Web of Science ®Google Scholar
• Lagrue K, Carisey A, Morgan DJ, et al. Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds. Blood. 2015 Jul 2;126(1):50–60.
   PubMed Web of Science ®Google Scholar
• Tai YT, Li XF, Catley L, et al. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res. 2005 Dec 15;65(24):11712–11720.
   PubMed Web of Science ®Google Scholar
• Benson DM Jr., Bakan CE, Zhang S, et al. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood. 2011 Dec 8;118(24):6387–6391.
   PubMed Web of Science ®Google Scholar
• Gandhi AK, Kang J, Havens CG, et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors ikaros and aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Br J Haematol. 2014 Mar;164(6):811–821.
   PubMed Web of Science ®Google Scholar
• Davies FE, Raje N, Hideshima T, et al.Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001 Jul 1;98(1):210–216.
   PubMed Web of Science ®Google Scholar
• Gorgun G, Samur MK, Cowens KB, et al. Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma. Clin Cancer Res 2015 Oct 15;21(20):4607–4618.
   PubMed Web of Science ®Google Scholar
• Bai A, Forman J The effect of the proteasome inhibitor lactacystin on the presentation of transporter associated with antigen processing (TAP)-dependent and TAP-independent peptide epitopes by class I molecules. J Immunol 1997;159(5):2139–2146.
   PubMed Web of Science ®Google Scholar
• Shi J, Tricot GJ, Garg TK, et al.Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma. Blood. 2008 Feb 1;111(3):1309–1317.
   PubMed Web of Science ®Google Scholar
• Yang G, Gao M, Zhang Y, et al.Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I. Oncotarget. 2015 Sep 29;6(29):26982–26994.
   PubMedGoogle Scholar
• Chang SK, Hou J, Chen GG, et al.Carfilzomib combined with ex vivo-expanded patient autologous natural killer cells for myeloma immunotherapy. Neoplasma. 2018 Sep 19;65(5):720–729.
   PubMed Web of Science ®Google Scholar
• Lee YS, Heo W, Nam J, et al. The combination of ionizing radiation and proteasomal inhibition by bortezomib enhances the expression of NKG2D ligands in multiple myeloma cells. J Radiat Res 2018 59(3):245–252.
   PubMed Web of Science ®Google Scholar
• Niu C, Jin H, Li M, et al.Low-dose bortezomib increases the expression of NKG2D and DNAM-1 ligands and enhances induced NK and γδ T cell-mediated lysis in multiple myeloma. Oncotarget. 2017 8(4):5954–5964.
   PubMedGoogle Scholar
• Feng X, Yan J, Wang Y, et al. The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells. Mol Immunol. 2010 Aug;47(14):2388–2396.
   PubMed Web of Science ®Google Scholar
• Wang X, Ottosson A, Ji C, et al.Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity. J Haematologica. 2009;94(4):470–478.
   PubMed Web of Science ®Google Scholar
• Kumaresan PR, Lai WC, Chuang SS, et al. CS1, a novel member of the CD2 family, is homophilic and regulates NK cell function. Mol Immunol. 2002 2002 Sep 15;39(1):1–8.
   PubMed Web of Science ®Google Scholar
• Hsi ED, Steinle R, Balasa B, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. J Clin Cancer Res. 2008;14(9):2775–2784.
   Google Scholar
• Collins SM, Bakan CE, Swartzel GD, et al.Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC [journal article]. Cancer Immunol 2013 December 01;62(12):1841–1849.
   Google Scholar
• Tai Y-T, Dillon M, Song W, et al.Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008;112(4):1329–1337.
   PubMed Web of Science ®Google Scholar
• Kurdi AT, Glavey SV, Bezman NA, et al. Antibody-dependent cellular phagocytosis by macrophages is a novel mechanism of action of elotuzumab. Mol Cancer Ther. 2018;17(7):1454–1463.
   PubMed Web of Science ®Google Scholar
• Zonder JA, Mohrbacher AF, Singhal S, et al.A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood. 2012;120(3):552–559.
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, Benson DM, Bensinger W, et al. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol 2012 Jun 1;30(16):1960–1965.
   PubMed Web of Science ®Google Scholar
• Lonial S, Vij R, Harousseau JL, et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol 2012 Jun 1;30(16):1953–1959.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Lonial S, Betts KA, et al. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. Cancer. 2018 Sep 11.
   Web of Science ®Google Scholar
• Lonial S, Dimopoulos M, Palumbo A, et al.Elotuzumab therapy for relapsed or refractory multiple myeloma. New Engl J Med 2015 Aug 13;373(7):621–631.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Dytfeld D, Grosicki S, et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. New Engl J Med 2018 Nov 8;379(19):1811–1822.
   PubMed Web of Science ®Google Scholar
• Jagannath S, Laubach J, Wong E, et al.Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. Br J Haematol 2018 182(4):495–503.
   PubMed Web of Science ®Google Scholar
• Plesner T, Krejcik J Daratumumab for the treatment of multiple myeloma. Front Immunol 2018 9:1228.
   PubMed Web of Science ®Google Scholar
• Casneuf T, Xu XS, Adams HC 3rd, et al. Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. Blood Adv 2017 Oct 24;1(23):2105–2114.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang Y, Hughes T, et al.Fratricide of NK cells in daratumumab therapy for multiple myeloma overcome by ex vivo-expanded autologous NK cells. Clin Cancer Res off J Am Assoc Cancer Res. 2018 Aug 15;24(16):4006–4017.
   PubMed Web of Science ®Google Scholar
• Fedele PL, Willis SN, Liao Y, et al.IMiDs through loss of ikaros and aiolos primes myeloma cells for daratumumab mediated killing by upregulation of CD38. Blood. 2018 Nov 15;132(20):2166–2178.
   PubMed Web of Science ®Google Scholar
• Bonifant CL, Jackson HJ, Brentjens RJ, et al.Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics. 2016 3:16011.
   PubMed Web of Science ®Google Scholar
• Chu J, Deng Y, Benson DM, et al.CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia. 2014 Apr;28(4):917–927.
   PubMed Web of Science ®Google Scholar
• Jiang H, Zhang W, Shang P, et al.Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. Mol Oncol. 2014 Mar;8(2):297–310.
   PubMed Web of Science ®Google Scholar
• Suck G, Odendahl M, Nowakowska P, et al. NK-92: an ‘off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy [journal article]. Cancer Immunol Immunother 2016 April 01;65(4):485–492.
   PubMed Web of Science ®Google Scholar
• Williams BA, Law AD, Routy B, et al.A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy. Oncotarget. 2017 8(51):89256–89268.
   PubMedGoogle Scholar
• Badros A, Hyjek E, Ma N, et al. Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma. Blood. 2017;130(10):1189–1197.
   PubMed Web of Science ®Google Scholar
• Shi J, Tricot G, Szmania S, et al.Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol 2008 Dec;143(5):641–653.
   PubMed Web of Science ®Google Scholar
• Shah N, Martin-Antonio B, Yang H, et al.Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS One 2013;8(10):e76781.
   PubMed Web of Science ®Google Scholar
• Shah N, Li L, McCarty J, et al.Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Br J Haematol 2017 177(3):457–466.
   PubMed Web of Science ®Google Scholar
• Lesokhin AM, Ansell SM, Armand P, et al.Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. 2016 Aug 10;34(23):2698–2704.
   PubMed Web of Science ®Google Scholar
• Ansell S, Gutierrez ME, Shipp MA, et al.A phase 1 study of nivolumab in combination with ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039). Blood. 2016;128(22): 183–183.
   Web of Science ®Google Scholar
• Mateos M-V, Blacklock H, Schjesvold F, et al. A phase 3 randomized study of pembrolizumab (Pembro) plus pomalidomide (Pom) and dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-183. J Clin Oncol. 2018;36(15_suppl): 8021–8021.
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Schjesvold F, Rocafiguera AO, et al. A phase 3 randomized study of pembrolizumab (pembro) plus lenalidomide (len) and low-dose dexamethasone (Rd) versus Rd for newly diagnosed and treatment-naive multiple myeloma (MM): KEYNOTE-185. J Clin Oncol. 2018;36(15_suppl): 8010–8010.
   Web of Science ®Google Scholar
• Gantke T, Reusch U, Kellner C, et al.AFM26 - targeting B cell maturation antigen (BCMA) for NK cell-mediated immunotherapy of multiple myeloma. Blood. 2017;130(Suppl 1): 3082–3082.
   Google Scholar
• Gantke T, Reusch U, Kellner C, et al. AFM26 is a novel, highly potent BCMA/CD16A-directed bispecific antibody for high affinity NK-cell engagement in multiple myeloma. Blood. 2017;35(15_suppl): 8045–8045.
   Google Scholar
• Xu W, Jones M, Liu B, et al.Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor alphaSu/Fc fusion complex in syngeneic murine models of multiple myeloma. Cancer Res. 2013 May 15;73(10):3075–3086.
   PubMed Web of Science ®Google Scholar
• San-Miguel J, Bladé J, Shpilberg O, et al.Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti–IL-6) in multiple myeloma. Blood. 2014;123(26):4136–4142.
   PubMed Web of Science ®Google Scholar
• Shah JJ, Feng L, Thomas SK, et al. Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial [original article]. Blood Cancer J. 2016 Feb 12 online;6:e396.
   PubMed Web of Science ®Google Scholar
• Nijhof IS, Lammerts van Bueren JJ, van Kessel B, et al. Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263–268.
   PubMed Web of Science ®Google Scholar
• Spear P, Barber A, Rynda-Apple A, et al. NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors. Immunol Cell Biol 2013;91(6):435–440.
   PubMed Web of Science ®Google Scholar
• Nikiforow S, Werner L, Murad J, et al.Safety data from a first-in-human phase 1 trial of NKG2D chimeric antigen receptor-T cells in AML/MDS and multiple myeloma. Blood. 2016;128(22): 4052–4052.
   PubMedGoogle Scholar
• Gogishvili T, Danhof S, Prommersberger S, et al.SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes. Blood. 2017;130(26):2838–2847.
   PubMed Web of Science ®Google Scholar
• Wang X, Wong CW, Urak R, et al.CS-1 re-directed central memory T cell therapy for multiple myeloma. Blood. 2014;124(21): 1114–1114.
   Web of Science ®Google Scholar
• Leivas A, Valeri A, Rio P, et al.Activated and expanded natural killer cells expressing an NKG2D-CAR efficiently target multiple myeloma cells. Blood. 2017;130(Suppl 1): 4466–4466.
   Google Scholar